Akari Therapeutics Plc — Director's Dealing 2014

Apr 8, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celsus Therapeutics Plc. (CLTX)
CIK: 0001541157
Period of Report: 2014-04-04

Reporting Person: SABBY MANAGEMENT, LLC (10% Owner)
Reporting Person: Sabby Healthcare Volatility Master Fund, Ltd. (10% Owner)
Reporting Person: Mintz Hal (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-04-04	Common Stock	P	1000	$6	Acquired	687951	Indirect
2014-04-04	Common Stock	P	11250	$6.08	Acquired	699201	Indirect
2014-04-07	Common Stock	P	16900	$5.64	Acquired	716101	Indirect
2014-04-07	Common Stock	P	3754	$6	Acquired	719855	Indirect
2014-04-08	Common Stock	P	35500	$5.36	Acquired	755355	Indirect

Footnotes

F1: This Form 4 is being filed by Sabby Healthcare Volatility Master Fund, Ltd. ("SHVMF"), Sabby Management, LLC ("Advisor") and Hal MIntz. The Advisor is the investment manager of SHVMF. Mr. Mintz is the manager of the Advisor.

F2: The amounts reported herein reflect the entire amount of the Issuer's securities held by SHVMF as of each transaction date. Each of the Advisor and Mr, Mintz disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934 ("Section 16"), beneficial ownership of such securities, except to the extent of its/his pecuniary interest therein, and this report shall not be deemed an admission that either the Advisor or Mr, Mintz is the beneficial owner of such securities for purposes of Section 16 or otherwise.